Industry
Biotechnology
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Loading...
Open
1.00
Mkt cap
30M
Volume
1.2M
High
1.04
P/E Ratio
-0.50
52-wk high
22.22
Low
0.99
Div yield
N/A
52-wk low
0.87
Portfolio Pulse from Benzinga Newsdesk
October 17, 2024 | 11:03 am
Portfolio Pulse from Avi Kapoor
October 03, 2024 | 9:24 am
Portfolio Pulse from Benzinga Newsdesk
August 16, 2024 | 11:04 am
Portfolio Pulse from Avi Kapoor
August 15, 2024 | 11:23 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 8:05 pm
Portfolio Pulse from Avi Kapoor
August 09, 2024 | 6:38 pm
Portfolio Pulse from Avi Kapoor
August 09, 2024 | 4:29 pm
Portfolio Pulse from Vandana Singh
August 09, 2024 | 4:15 pm
Portfolio Pulse from Benzinga Newsdesk
August 09, 2024 | 1:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.